StockData
CASI Pharmaceuticals, Inc. logo

CASI Pharmaceuticals, Inc. (CASIF) stock

CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on May 15, 2026Score 1/30
$0.10+0.00 (0.00%)

Close on Oct 19, 2026Market cap –P/E –Yield –

How the market prices CASI Pharmaceuticals

Each ratio against its own distribution since 2021, from month-end prices and the figures reported at the time

CASI Pharmaceuticals trades at 0.1× its earnings, against a median of 1.1× since 2021 — cheaper than 100% of the months in between.

The shaded bar covers the 5th to 95th percentile of month-end values since 2021, the darker part the 25th to 75th, the line the median and the dot today. The figure on the right is the percentile today sits at.

Price to sales since 2021

Median 1.1×, today 0.1×

What CASI Pharmaceuticals keeps of every dollar

Trailing twelve months, from revenue down to net income. Grey columns are what comes out.

Margins against the industry

Gross margin48.6%vs 52.8%
Operating margin-217.3%vs -42.9%
EBITDA margin-211.5%vs -29.3%
Pretax margin-221.5%vs -13.0%
Net margin-232.0%vs -39.9%
Free cash flow margin-100.3%vs -9.41%

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

What it earns on the capital it uses

Trailing twelve months over average capital

Return on assets-121.2%vs -40.7%

How hard the assets work

Revenue per dollar of assets0.52vs 0.39
Inventory turns a year3.11vs 2.68
Revenue per employee$96.79Kvs $405.05K
Profit per employee-$224.57Kvs -$704.12K

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

What it owes and what covers it

Latest balance sheet, against twelve months of cash generation

Borrowings exceed cash by $13.56M.

Total debt$19.19M
Cash and short-term investments$5.63M
EBITDA, trailing twelve months-$43.81M
Free cash flow, trailing twelve months-$20.77M

Leverage and liquidity

Current ratio0.27vs 3.28
Quick ratio0.20vs 2.37

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

Scores and rules of thumb

Academic scores computed from the latest two fiscal years. They are screens, not verdicts.

Piotroski F-Score

Nine yes-or-no tests of profit, leverage and efficiency against last year.

4 of 9 tests passed

Beneish M-Score

Eight variables that flag accounts shaped to look better than they are.

-8.79
No flagManipulation risk

How the shares have traded

Total return includes reinvested dividends, to the close on Oct 19, 2026

Total return against the S&P 500

The axis is compressed: each step is ten times the one before, so a month and a decade fit on the same line.

CASIFS&P 500
PeriodCASIFS&P 500DifferenceCASIF per yearS&P 500 per year
1 month-22.3%+0.6%−22.9 pts
3 months-39.7%+3.4%−43.1 pts
Year to date-88.2%+13.3%−101.5 pts
1 year-94.2%+16.6%−110.9 pts
3 years-97.2%+86.4%−183.6 pts-69.7%+23.1%
5 years-99.1%+81.9%−181.0 pts-61.0%+12.7%
10 years-99.3%+318.9%−418.1 pts-38.9%+15.4%

Who is betting against it

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M CASIF shares were sold short on Oct 30, 2026, up 0.0% from the previous report. At recent volumes it would take 32.8 days to buy them back.

Shares sold shortDays to cover

The last twelve reports

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 2026144,4310.0%4,40032.8
Oct 15, 2026144,4310.0%3,22244.8
Sep 30, 2026144,431-0.1%1,51095.7
Sep 15, 2026144,5040.0%5,41026.7
Aug 31, 2026144,5040.0%2,76952.2
Aug 14, 2026144,5040.0%4,10535.2
Jul 31, 2026144,5040.0%1,66187.0
Jul 15, 2026144,5040.0%7,93818.2
Jun 30, 2026144,504-49.0%8,61116.8
Jun 15, 2026283,470-7.2%53,8065.3
May 29, 2026305,345-2.8%8,16437.4
May 15, 2026314,130-1.4%19,31416.3

Every measure, in full

41 figures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
–
Last ex-dividend date
No dividends
Fundamentals through
Dec 31, 2025
Share price as of
–

Share statisticsIndustry

Shares Change (YoY)
20.8%
11.0%
Shares Held by Institutions
0.00%
56.3%

MarginsIndustry

Gross Margin
48.6%
52.8%
Operating Margin
-217.3%
-42.9%
Pretax Margin
-221.5%
-13.0%
Profit Margin
-232.0%
-39.9%
EBITDA Margin
-211.5%
-29.3%
FCF Margin
-100.3%
-9.41%

Returns on capitalIndustry

Return on Assets (ROA)
-121.2%
-40.7%

Financial positionIndustry

Current Ratio
0.27
3.28
Quick Ratio
0.20
2.37

GrowthIndustry

Revenue Growth (YoY)
-27.4%
5.68%
Revenue Growth (3Y CAGR)
-21.7%
2.25%
Revenue Growth (5Y CAGR)
6.47%
6.41%

EfficiencyIndustry

Asset Turnover
0.52
0.39
Inventory Turnover
3.11
2.68
Revenue Per Employee
$96.79K
$405.05K
Profits Per Employee
-$224.57K
-$704.12K
Employee Count
214
75

Income statement (TTM)Industry

Revenue
$20.71M
$58.79M
Gross Profit
$10.08M
$103.58M
Operating Income
-$45.01M
-$21.49M
Pretax Income
-$45.87M
-$14.83M
Net Income
-$48.06M
-$22.47M
EBITDA
-$43.81M
-$17.14M
EPS (Diluted)
-$2.59
-$0.83

Balance sheetIndustry

Total Debt
$19.19M
$114.91M
Net Cash (Debt)
-$13.56M
$15.31M
Net Cash Per Share
-$0.66
$0.72
Equity (Book Value)
-$37.28M
$49.40M
Book Value Per Share
-$1.81
$1.45
Tangible Book Value
-$37.50M
$23.58M
Working Capital
-$36.21M
$74.34M

Cash flow (TTM)Industry

Operating Cash Flow
-$20.75M
-$12.17M
Capital Expenditures
-$16.00K
-$1.02M
Free Cash Flow
-$20.77M
-$20.44M
FCF Per Share
-$1.01
-$0.42

Scores and fair valueIndustry

Piotroski F-Score
4
4
Beneish M-Score
-8.79
-2.62

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?